Table 2 Prevalence of retinal NV and associated risk factors<sup>†</sup>

Characteristics	No Retinal NV	Retinal NV	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)
Number of Eyes	13,704	106 (0.77%)		
Age<35 (compared to age>35)	5,357 (39%)	57 (54%)	1.8 (1.2 - 2.9)*	2.0 (1.2 – 3.4)*
Female (compared to male)	8,598 (63%)	64 (60%)	0.90 (0.57 - 1.4)	0.90 (0.56 - 1.5)
Behçet Disease	322 (2.4%)	4 (3.8%)	1.6 (0.59 - 4.5)	0.63 (0.22 – 1.8)
Systemic lupus erythematosus	114 (0.83%)	4 (3.8%)	4.7 (1.1 - 20)*	2.9 (0.69 - 13)
Sarcoidosis	911 (6.7%)	9 (8.5%)	1.3 (0.57 - 3.0)	1.3 (0.55 - 2.9 )
HLA-B27+	1550 (11%)	0	0 (0 – 2.8) **	0 (0 – 0.9) **
HLA-A29+	275 (2.0%)	1 (0.94%)	0.47 (0.060 - 3.4)	0.15 (0.020 - 1.1)
Polyarteritis nodosa	16 (0.12%)	0	0 (0 - 35) **	0 (0 - 27) **
Granulomatosis with polyangiitis	8 (0.06%)	0	0 (0 - 80) **	0 (0 - 48) **
Other arteritis	8 (0.06%)	0	0 (0 – 80) **	0 (0 – 38) **
Scleroderma	10 (0.07%)	0	0 (0 – 6.1) **	0 (0 – 38) **
Sjögren's syndrome	22 (0.16%)	0	0 (0 – 25) **	0 (0 – 25) **
Spondyloarthropathy (any)	755 (5.43%)	0	0 (0 – 0.64) **	0 (0 – 2.2) **
Polymyositis	5 (0.04%)	1 (0.94%)	26 (3.8 – 181) **	41 (16.4 – 101) **
Rheumatoid arthritis	228 (1.7%)	2 (1.9%)	1.1 (0.16 – 8.3)	1.3 (0.15 – 11)
Juvenile idiopathic arthritis	724 (5.3%)	2 (1.9%)	0.34 (0.08 – 1.4)	0.68 (0.15 – 3.0)
Relapsing polychondritis	22 (0.16%)	0	0 (0 – 25) **	0 (0 – 139) **
Cogan's syndrome	8 (0.06%)	0	0 (0 – 80) **	0 (0 – 255)
Crohn's disease	180 (1.3%)	0	0 (0 – 2.8) **	0 (0 – 5.4) **
Ulcerative Colitis	174 (1.3%)	0	0 (0 – 2.9) **	0 (0 – 4.6) **
Multiple Sclerosis	193 (1.4%)	3 (2.83%)	2.0 (0.46 – 9.0)	1.9 (0.4 – 9.1)
Familial systemic granulomatosis	8 (0.06%)	0	0 (0 – 80) **	0 (0 – 67) **
Hypertension	2,587 (19%)	23 (21%)	1.2 (0.68 - 2.1)	1.3 (0.71 - 2.4)
Diabetes	783 (5.7%)	7 (6.4%)	1.2 (0.53 – 2.5)	1.4 (0.61 - 3.2)

Characteristics	No Retinal	Retinal NV	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)
Bilateral uveitis	9,661 (71%)	97 (92%)	4.5 (2.3 – 9.0)**	2.6 (1.3 - 5.3)**
Current Smoker (compared to never smoker)	2,364 (17%)	24 (23%)	1.8 (1.0 - 3.9)*	1.5 (0.81 - 2.6)
Former Smoker (compared to never smoker)	1,386 (10%)	8 (7.6%)	1.0 (0.39 - 2.7)	0.99 (0.36 - 2.7)
Uveitis diagnosis ≤ 1 year (vs >5 years)	6,505 (47%)	53 (50%)	2.1 (0.99-4.3)	1.7 (0.81 – 3.6)
Uveitis diagnosis between 1 and 5 years (vs >5 years)	3,900 (28%)	40 (38%)	2.6 (1.2 - 5.5)*	2.2 (1.0 - 4.6)*
Site of inflammation				
Anterior uveitis	7,820 (57%)	12 (11%)	1.0 (reference group)	1.0 (reference group)
Intermediate uveitis	2,197 (16%)	21 (20%)	6.2 (2.7 - 14)**	4.5 (1.9 - 10)**
Posterior uveitis	2,116 (15%)	52 (49%)	16 (7.7 - 33)**	12 (5.9 - 26)**
Panuveitis	1,571 (11%)	21 (20%)	8.7 (3.8 - 20)**	6.6 (2.8 - 15)**
Activity				
Inactive inflammation	4,781 (42%)	24 (23%)	1.0 (reference group)	1.0 (reference group)
Slightly active inflammation	1,569 (14%)	25 (24%)	3.2 (1.6 - 6.2)**	2.3 (1.2 - 4.6)*
Active inflammation	5,128 (45%)	55 (53%)	2.1 (1.2 - 3.8)*	1.5 (0.84 - 2.6)
Anterior Chamber Cell				
No Cell	6,408 (56%)	64 (60%)	1.00	1.00
0.5+	1,869 (16%)	23 (22%)	1.2 (0.71 - 2.1)	1.5 (0.88 - 2.6)
1+	1,439 (13%)	5 (4.7%)	0.35 (0.14 - 0.88)*	0.51 (0.20 - 1.3)
2+	1,138 (9.9%)	12 (11%)	1.1 (0.52 - 2.2)	1.7 (0.78 - 3.5)
3+	640 (5.6%)	2 (1.9%)	0.31 (0.08 - 1.3)	0.51 (0.12 - 2.2)
Vitreous Cell				
No Cell	6,225 (58%)	29 (28%)	1.00	1.00
0.5+	1,358 (13%)	22 (21%)	3.5 (1.8 - 6.6)**	2.6 (1.3 - 5.1)**
1+	1,631 (15%)	27 (26%)	3.6 (1.9 - 6.5)**	2.5 (1.4 - 4.5)**
2+	1,187 (11%)	22 (21%)	4.0 (2.1 - 7.4)**	2.7 (1.4 - 5.0)**

Characteristics	No Retinal NV	Retinal NV	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)
3+	398 (3.7%)	5 (4.8%)	2.7 (1.0 - 7.2)*	1.9 (0.7 - 5.3)
Vitreous Haze				
None	8,443 (82%)	77 (78%)	1.00	1.00
1+	1,138 (11%)	14 (14%)	1.35 (0.76 - 2.4)	0.87 (0.48 - 1.6)
2+	465 (4.5%)	7 (7.1%)	1.7 (0.62 - 4.4)	1.3 (0.5 - 3.5)
3+	193 (1.9%)	1 (1.0%)	0.57 (0.08 - 4.1)	0.43 (0.06 - 3.3)
Macular edema	1,603 (11%)	30 (28%)	3.0 (1.8 - 4.9)**	2.1 (1.2 - 3.5)**
Epiretinal membrane	586 (4.3%)	23 (22%)	6.2 (3.7 - 11)**	4.5 (2.6 - 7.8)**
Exudative retinal detachment	162 (1.2%)	5 (4.7%)	4.1 (1.7 – 10.2)**	2.1 (0.83 - 5.5)
Choroidal NV	77 (0.56%)	4 (3.8%)	6.9 (2.5 - 19)**	2.7 (0.90 - 8.1)
Snowballs present	788 (5.8%)	3 (2.8%)	0.48 (0.15 - 1.5)	0.30 (0.090 - 0.98)*
Retinal vascular sheathing	859 (6.3%)	16 (15%)	2.7 (1.4 - 5.0)**	1.1 (0.6 - 2.0)
Retinal vascular occlusion	73 (0.53%)	8 (7.6%)	15 (6.6 - 35)**	4.7 (1.9 - 11)**
Active inflammatory chorioretinal lesions	904 (6.6%)	9 (8.5%)	1.3 (0.6 – 3.0)	0.40 (0.17 - 0.92)*

<sup>&</sup>lt;sup>†</sup>Adjusted analysis adjusts for age category, gender, bilateral inflammation, smoking status, hypertension, diabetes, time from diagnosis, and systemic lupus erythematosus.

These conditions with low numbers of retinal neovascularization are available in supplemental tables online and omitted from the print versions for brevity. Data reporting risk based on gradings of anterior chamber cell, vitreous cell, and vitreous haze are available in the supplemental table.

Takayasu arteritis and dermatomyositis had fewer than 5 observations in both the prevalence and incidence analyses and are omitted from the tables.

<sup>&</sup>lt;sup>††</sup>For characteristics which were not present in any patients with retinal NV, an odds ratio (OR) of zero is given but an estimated confidence interval is calculated using a profile likelihood method (see text for details).

<sup>\*=</sup>p<0.05

<sup>\*\*=</sup>p<0.01